TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy

To assess the TANTALUS therapy in type 2 diabetic patients who can not tolerate GLP-1 agonist due to unacceptable side effects; and to assess the TANTALUS therapy in type 2 diabetic patients who do not sufficiently benefit from GLP-1 receptor agonist therapy

Study Overview

• Status: Terminated
• Conditions: Diabetes Mellitus, Type 2
• Intervention / Treatment: Device: TANTALUS System

Detailed Description

The present protocol will address whether the effects of the TANTALUS treatment are complimentary to GLP-1 treatment which is only partially effective or whether it can replace GLP-1 treatment in individuals who cannot tolerate GLP-1 agonists because of unacceptable side effects.

This investigation will be a 3 arm multicenter study which will enroll in a Run-In Period up to 400 with type 2 diabetes mellitus. This Run-In Period will facilitate screening the patients with the aim to have a maximum of 30 patients in each arm complete the Evaluation Period of 6 months. The study aims at evaluating the TANTALUS therapy compared to GLP-1 receptor agonist therapy by evaluating improvement in glycemic control and weight after 6 months of treatment in each of the 3 study groups, which are:

• Group A: subjects on GLP-1 receptor agonist therapy only
• Group B: subjects on GLP-1 receptor agonist therapy and TANTALUS therapy
• Group C: subjects on TANTALUS therapy only

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Czech Republic
  • Brno, Czech Republic, 656 91
    • Fakultni Nemocnice u sv. Anny v Brne
  • Hradec Kralove, Czech Republic, 500 05
    • Klinika gerontologická a metabolická,
  • Prague, Czech Republic, 128 08
    • General University Hospital,
  • Prague, Czech Republic, 130 00
    • Prednosta OB Kliniky a.s.,
• Germany
  • Bad Mergentheim, Germany
    • Diabetes Zentrum
  • Hamburg, Germany, 20099
    • Asklepios Klinik St. Georg
  • Münster, Germany, 48153
    • Diabetes-Praxis Muenster
• Romania
  • Bucharest, Romania, 79811
    • 'N. Paulescu' National Institute of Diabetes, Nutrition and Metabolic Diseases
  • Bucharest, Romania, A
    • CMI Dr Busegeanu Mihaela Magdalena-Ploiesti
  • Bucharest, Romania, A
    • Fundeni Hospital - Surgical
  • Bucharest, Romania, A
    • Sanatatea Ta Medical Center
  • Bucharest, Romania, A
    • Sf. Ioan Hospital - Surgical
  • Bucharest, Romania, A
    • Spitalul Pelican, Orada

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 70 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male and female subjects 21 through 70 years of age
2. Type 2 diabetes duration more than 6 months and less than 10 years
3. 7.8% < HbA1c < 10.5% if T2DM duration less than or equal to 5 years
4. 7.8% < HbA1c < 10.0% if T2DM duration more than 5 years
5. BMI < 40 kg/m2
6. Taking at least one oral anti-diabetic medication

7. Patients treated with GLP-1 receptor agonist with at least one oral anti-diabetic medication may be included under the following conditions:

   a. The HbA1c, before GLP-1 receptor agonist therapy was administered, was: i. 7.8% < HbA1c < 10.5% if T2DM duration less than 5 years ii. 7.8% < HbA1c < 10.0% if T2DM duration greater than 5 years b. The patient was on GLP-1 receptor agonist therapy for no more than 12 weeks

8. Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods
9. If subject is taking lipid-lowering medication, the treatment must be stable for at least one month prior to enrollment
10. If subject is taking anti-hypertensive medication, the treatment must be stable for at least one month prior to enrollment
11. If subject is taking anti-depressant medication, the treatment must be stable for at least one month prior to enrollment
12. Willingness to refrain from using prescription, over the counter, or herbal weight loss products for the duration of the trial
13. Ability and willingness to perform required study and data collection procedures and adhere to operating requirements of the TANTALUS® System
14. Alert, mentally competent, and able to understand and willing to comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial
15. Able to provide voluntary informed consent

Exclusion Criteria:

1. Insulin therapy within the last 3 months 2. GLP-1 receptor agonist therapy longer than 3 months 3. Diagnosed with renal dysfunction or history of renal dysfunction 4. Taking medications known to affect gastric motility 5. Use of prescription, over the counter or herbal weight loss products or obesity drugs during the past two months 6. Experiencing severe and progressing diabetic complications (7. Prior wound healing problems 8. Diagnosed with past or current psychiatric condition that may impair his or her ability to comply with the study procedures 9. Use of anti-psychotic medications 10. Diagnosed with eating disorder such as bulimia or binge eating 11. Obesity due to an endocrinopathy 12. Hiatal hernia requiring surgical repair or a paraesophageal hernia 13. Pregnant or lactating 14. Diagnosed with impaired liver function 15. Any prior bariatric surgery 16. Any history of pancreatitis 17. Any history of peptic ulcer disease within 5 years of enrollment 18. Diagnosed with Gastroparesis or other GI motility disorder 19. Use of active medical devices (either implantable or external) such as ICD, drug infusion device, or neurostimulator (either implanted or worn). Subjects using an external active device who are able and willing to avoid use of the device during the study may be enrolled.

20. Cardiac history that physician feels should exclude the subject from the study.

21. Use of another investigational device or agent in the 30 days prior to enrollment 22. A history of life-threatening disease within 5 years of enrollment 23. Any additional condition(s) that in the Investigator's opinion would warrant exclusion from the study or prevent the subject from completing the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
OTHER: GLP-1 receptor agonist therapy; Group A: Subjects on GLP-1 receptor agonist therapy only. After run in of 12 weeks on GLP-1 receptor agonist therapy, Patients with HbA1c < 7.5 are moved to Group A, continue GLP-1 receptor agonist therapy, and then start the Evaluation Period These patients will not be implanted with the TANTALUS system.	Device: TANTALUS System; An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity; Other Names: TANTALUS System, TANTALUS II
EXPERIMENTAL: GLP-1 receptor agonist and TANTALUS; Group B: subjects on GLP-1 receptor agonist therapy and TANTALUS therapy After run in of 12 weeks on GLP-1 receptor agonist therapy, Patients with HbA1c > 7.5 are moved to Group B, continue GLP-1 receptor agonist therapy, implanted with TANTALUS within 4 weeks, and then start the Evaluation Period	Device: TANTALUS System; An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity; Other Names: TANTALUS System, TANTALUS II
ACTIVE_COMPARATOR: Subjects on TANTALUS therapy only; Group C: subjects on TANTALUS therapy only After run in of 12 weeks on GLP-1 receptor agonist therapy, patients intolerant to low dosage of GLP-1 receptor agonist therapy will be implanted with the TANTALUS system	Device: TANTALUS System; An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity; Other Names: TANTALUS System, TANTALUS II

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Decrees in HbA1c of at least 0.5 points and Weight loss of at least 3% of total body weight after 6 month of treatment	Change in HbA1c and weight will be assessed at baseline and 24 weeks of treatment for Group A and C. Additionally, each group will be analyzed for the weight of decrease extent, the percentage of patients achieving the endpoint, and the percentage of patients that reach an HbA1c less than 7.0%.	6 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Glycemic and metabolic parameters	Glycemic Parameters (FBG, PPG); Glycemic Dynamics (Glucose, Insulin, C-Peptide, and Glucagon Profiles) via MTT; Metabolic Parameters (WC, BP, Lipids, Gastric Emptying); Gastric Hormones (GLP-1, GIP, Ghrelin, PYY, Pancreatic Polypeptide) via MTT	6 month

Collaborators and Investigators

• Sponsor: MetaCure (USA), Inc.
• Investigators: Study Director: Walid Haddad, PhD, MetaCure Limited

Study record dates

Study Major Dates

• Study Start: January 1, 2011
• Primary Completion (ACTUAL): July 1, 2011
• Study Completion (ACTUAL): July 1, 2011

Study Registration Dates

• First Submitted: February 23, 2011
• First Submitted That Met QC Criteria: February 23, 2011
• First Posted (ESTIMATE): February 24, 2011

Study Record Updates

• Last Update Posted (ESTIMATE): September 22, 2016
• Last Update Submitted That Met QC Criteria: September 21, 2016
• Last Verified: June 1, 2011

More Information

Terms related to this study

• Keywords: C19 246 300
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2
• Other Study ID Numbers: MC CPTAN2010-017; Position II (OTHER: MetaCure)